Exalenz Bioscience (Israel) Financial Diagnostics

EXEN -- Israel Stock  

ILS 737.50  28.60  4.03%

The big decline in price over the last few months for Exalenz Bioscience could raise concerns from investors as the firm closed today at a share price of 737.5 on 805.000 in volume. The company executives failed to add value to investors and positioning the firm components to exploit market volatility in March. However, diversifying your holdings with Exalenz Bioscience Ltd or any similar stocks can still protect your portfolios during high-volatility market scenarios. The stock standard deviation of daily returns for 30 days (very short) investing horizon is currently 3.121. The above-average volatility is mostly attributed to market volatility and speculations regarding some of the upcoming earning calls from Exalenz Bioscience partners. This diagnostics interface makes it easy to digest most current publicly released information about Exalenz Bioscience as well as get updates on important government artifacts including earning estimates, SEC corporate filings and announcements. This module also helps to analysis Exalenz Bioscience price relationship with some important fundamental indicators such as market cap and management efficiency. Additionally see Investing Opportunities.

Exalenz Bioscience Note

The company recorded loss per share of 0.17. Exalenz Bioscience had not issued any dividends in recent years. The entity had 1:100 split on 2014-12-21. Exalenz Bioscience Ltd. develops and markets advanced tools for the diagnosing and managing liver and gastroenterology disorders in Israel. Exalenz Bioscience Ltd. is based in Modiin-Maccabim-Reut, Israel. Exalenz Bioscience is traded on Tel Aviv Stock Exchange in Israel. To learn more about EXALENZ BIOSCIENC call the company at 972 8 973 7500 or check out http://www.exalenz.com.

Exalenz Bioscience Alerts

Exalenz Bioscience is not yet fully synchronised with the market data
Exalenz Bioscience generates negative expected return over the last 30 days
Exalenz Bioscience has high historical volatility and very poor performance
The company reported revenue of 12.82M. Net Loss for the year was (4.37M) with profit before overhead, payroll, taxes, and interest of 3.58M.
EXALENZ BIOSCIENC has accumulated about 4.77M in cash with (7.35M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.18.

Market Capitalization

The company currently falls under 'Small-Cap' category with current market capitalization of 234.8M.


The company has Profit Margin (PM) of (34.07) % which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (36.78) % which suggests for every $100 dollars of sales it generated a net operating loss of -0.37.

Management Efficiency

Exalenz Bioscience has return on total asset (ROA) of (24.33) % which means that it has lost $24.33 on every $100 spent on asset. This is way below average.

Exalenz Bioscience Technical and Predictive Indicators

Did you try this?

Run Insider Screener Now


Insider Screener

Find insiders across different sectors to evaluate their impact on performance
All  Next Launch Module
Additionally see Investing Opportunities. Please also try Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
Search macroaxis.com